A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Pfizer

Status: Active, not recruiting

Conditions: Transthyretin Amyloid Cardiomyopathy

Treatments: Drug: Tafamidis 61 milligrams

Study type: Observational

Funder types: Industry

Identifiers

NCT06321523

B3461122

Details and patient eligibility

About

The purpose of this clinical trial is to learn about the effects of the study medicine (called Tafamidis 61milligrams (mg)) for the potential treatment of Transthyretin amyloid cardiomyopathy (ATTR-CM).

This study is seeking participants who were prescribed Tafamidis 61mg after being diagnosed with ATTR-CM and have taken Tafamidis 61mg at least once.

We will examine the experiences of people receiving the study medicine. This will help us determine if the study medicine is safe and effective.

Enrollment: 13 patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥19 years
• Patients diagnosed with ATTR-CM (ATTRwt and ATTRv) with tissue biopsy or nuclear scintigraphy
• Patients who was prescribed Tafamidis 61mg after being diagnosed with ATTR-CM and have taken Tafamidis 61mg at least once.

Exclusion criteria

• Presence of other amyloidosis

Trial design

13 participants in 1 patient group

ATTR-CM patients in Korea

Description:

transthyretin amyloid cardiomyopathy (ATTR-CM) patients in Korea

Treatment:

Drug: Tafamidis 61 milligrams